In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.
Ortho Regenerative Technologies changed its name to ChitogenX in September 2022.
"We evaluated our Company name in light of the vast potential clinical and commercial applications for our proprietary technology platform, and it was obvious that these applications were much broader than just the orthopedic field the previous corporate name was inferring to," CEO Philippe Deschamps said in a news release. "We opted for a new company name that better represented our identity and expanded possibilities."
Similarly, Aziyo Biologics said on Sept. 6 that it was rebranding as Elutia to reflect a focus on drug eluting biomatrices.
"There is a clear need in surgery for the power of local drug delivery paired with the wound healing benefits of biological materials," CEO Randy Mills, PhD, said in a news release. "Our first new product will be for the pacemaker and implantable defibrillator markets where surgical complications have devastating consequences for patients."
Both companies have histories in orthopedics. In 2020, ChitogenX was focused on its Ortho-R hybrid implant. Elutia produced bone grafts, but the company went into talks to divest its orthopedic segment completely, according to an Aug. 14 announcement.